Servier Reinforces Commitment to Cancer Research and Patient Care on World Cancer Day

Servier Reinforces Commitment to Cancer Research and Patient Care on World Cancer Day

(IN BRIEF) On World Cancer Day, Servier reaffirms its commitment to the fight against cancer by focusing on oncology as a central part of its Research & Development efforts. The company emphasizes the importance of understanding the personal experiences of cancer patients to develop more tailored treatments. Servier’s investment in immuno-oncology and targeted therapies aims to address growing cancer challenges, particularly in rare cancers and hematological diseases. In addition to its medical initiatives, Servier supports cancer patients through educational programs like SHAPE, which provide guidance on managing various aspects of their journey. Servier’s efforts have been recognized in the global PatientView rankings, highlighting its significant role in advancing cancer care.

(PRESS RELEASE) PARIS, 4-Feb-2025 — /EuropaWire/ — Servier is reaffirming its commitment to the fight against cancer on World Cancer Day by highlighting its ongoing dedication to oncology research. With nearly 20 million new cancer cases diagnosed worldwide each year and projections indicating that this number will exceed 32 million by 2045, Servier is focusing its research and development efforts on oncology to meet the growing therapeutic demands. On this global awareness day, Servier emphasizes the need for continued progress in cancer treatment, with a special focus on the unique personal experiences of patients battling cancer.

World Cancer Day, organized by the Union for International Cancer Control (UICC), aims to raise awareness about cancer prevention and encourage global involvement in combating this widespread health challenge. The 2025 anti-cancer campaign, titled “United by Unique,” explores the diverse and personal stories of cancer patients, underscoring the importance of considering each patient’s experience in their treatment plan. This philosophy aligns with Servier’s approach to personalized care, where the patient’s individual needs are central to the development of therapeutic solutions.

Cancer remains the second leading cause of death globally, claiming the lives of almost 10 million people each year. Although factors such as smoking, poor diet, and physical inactivity contribute to the disease burden, early detection, regular screening, and appropriate treatment could prevent a third of cancer-related deaths. Servier continues to address these challenges by directing over 70% of its Research & Development budget to oncology, particularly focusing on rare cancers, digestive cancers, brain tumors, and hematological cancers.

As part of its ambitious strategy, Servier is investing heavily in immuno-oncology and targeted therapies. These two promising approaches aim to activate the immune system to fight cancer and target specific biological mechanisms within cancer cells. Servier’s oncology pipeline currently includes 30 projects, 16 in development and 14 in research, with eight medicines already available to healthcare professionals and patients.

Servier’s commitment to supporting cancer patients extends beyond medicine. Through initiatives like the SHAPE program (Support Harmonized Advances for better Patient Experiences), the company provides educational resources and practical advice to cancer patients, helping them manage their journey from diagnosis to recovery. The educational guides, co-created with patient experts, caregivers, and healthcare professionals, focus on key aspects such as emotional health, physical activity, nutrition, and communication with medical staff.

In recognition of its efforts, Servier has been ranked among the top pharmaceutical companies in oncology by PatientView, achieving high rankings in the U.S. and globally. This recognition underscores Servier’s ongoing dedication to advancing cancer care and improving patient outcomes worldwide.

Media Contact:

presse@servier.com

SOURCE: Servier

MORE ON SERVIER, ETC.:

Follow EuropaWire on Google News
EDITOR'S PICK:

Comments are closed.